Phaseline

Companies › 35Pharma Inc., a GSK company

35Pharma Inc., a GSK company: clinical trials, targets and expected readouts

1 active drug program in 2 registered trials: 2 Phase 1; Cardiovascular; next expected readout Mar 2028.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
HS235
Activin signaling inhibitor
–Phase 1Pulmonary Arterial Hypertension; Pulmonary HypertensionMar 2028

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT07143448HS235Phase 1Pulmonary Arterial HypertensionCardiovascularMar 2028
NCT07123779HS235Phase 1Pulmonary HypertensionCardiovascularJan 2029

From the company's SEC filings

Cash of 3.4bn GBP on 2025-12-31; operating cash flow positive

Targets

No annotated target.

Companies with the same targets

–

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.